Roivant reports strong trial results and $2.25B Moderna settlement, boosting cash to $4.3B with key drug launches planned in 2026

Moderna surges 63% YTD on Q1 revenue spike, but Gilead offers steadier cash flow and dividends for long-term investors.

Moderna's stock jumped 63.17% year to date after a surprising Q1 revenue triple and pipeline optimism, but its long-term outlook remains weak with declining revenue and cash burn. In contrast, Gilead Sciences presents a stronger investment case with ...